ModernVivo

ModernVivo is an AI-powered literature review platform purpose-built for in vivo study design. By automatically extracting and synthesising insights from thousands of scientific papers, ModernVivo enables preclinical researchers to accelerate study design, reduce costs, and improve translational success — all without spending months manually scouring databases.

Trusted by leading universities and institutions, ModernVivo serves drug discovery companies, contract research organisations (CROs), academic labs, and IACUC committees. The platform is engineered by in vivo scientists who understand the practical demands of preclinical research, ensuring that every feature is immediately applicable to real-world workflows.

Core Platform Capabilities

• Fully tailored searches: Move beyond simple keyword matching to pinpoint precisely the information needed for a given project, drawing on hands-on in vivo expertise baked into the search engine.
• Data-driven decision making: ModernVivo distils key points from thousands of papers instantly, removing irrelevant content and delivering actionable insights for gold-standard in vivo work.
• Real-time analytics and updates: Stay current with emerging research through real-time analytics and continuously updated literature insights.
• Detailed data visualisation: Presents research findings in clear, visual formats that support methodological accountability and transparent study design.
• Customisable and adaptable features: User-defined study parameters can be configured to match the specific needs of each research project or organisation.

Key Benefits for Researchers and Organisations

• Minimise timelines: Preclinical workflows are accelerating — ModernVivo helps researchers catch the first wave of data-driven literature reviews and reimagine preclinical deadlines.
• Reduce costs: In vivo work is expensive and complex. Getting study details right the first time eliminates the time and expense of repeat experiments.
• Optimise study design: Extracting wisdom from thousands of papers instantly ensures studies are built on the most comprehensive and up-to-date evidence base available.
• Use fewer animals: Smarter, more informed study design helps researchers adhere to the 3Rs principles — Replacement, Reduction, and Refinement — minimising unnecessary animal use.

Who ModernVivo Is Designed For

• Drug discovery companies: Automates the labour-intensive process of in vivo study design, delivers precise data-driven insights, reduces the risk of costly experimental errors, and helps bring new therapies to market faster while cutting operational costs.
• Contract research organisations (CROs): Streamlines in vivo study designs, optimises resources, increases study throughput, and eliminates manual literature searches — enabling CROs to handle more projects and deliver results faster while improving study design quality.
• Academic labs: Enables researchers to quickly find and extract relevant experimental parameters from vast literature, saving time for groundbreaking discoveries and ensuring studies are built on comprehensive, up-to-date data.
• IACUC committees: Provides a reliable solution for assessing study designs with precision and ethical rigour, automating extraction of key experimental parameters to support compliance with the 3Rs and facilitate confident, data-backed protocol review.

Usability and Workflow Integration

• Intuitive user interface designed to simplify complex searches and unpack user-defined study parameters with minimal friction.
• Engineered for seamless integration into pre-existing research workflows, reducing the learning curve for adoption.
• Comprehensive literature insights are delivered in a transparent manner, encouraging methodological accountability and enabling researchers to redefine study design with confidence.

ModernVivo is powered in part by Semantic Scholar and is available as an open platform. The company supports its user community with a growing resource library including case studies, whitepapers, and blog content focused on preclinical R&D and AI-driven study design.